Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections-Reference-Cited by-同舟云学术

Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections

Published:2019-01 Issue:1 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Chojnacki Michaelle¹,Philbrick Alesa¹,Wucher Benjamin¹,Reed Jordan N.¹,Tomaras Andrew²,Dunman Paul M.¹,Wozniak Rachel A. F.³

Affiliation:

1. Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

2. BacterioScan, St. Louis, Missouri, USA

3. Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

Abstract

Staphylococcus aureus and Pseudomonas aeruginosa are two of the most common causes of bacterial keratitis and corresponding corneal blindness. Accordingly, such infections are predominantly treated with broad-spectrum fluoroquinolones, such as moxifloxacin.

Funder

Arcum Therapeutics

Research to Prevent Blindness

HHS | NIH | National Eye Institute

University of Rochester

American Society of Cataract and Refractive Surgery

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01929-18